Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.

摘要

In patients with aplastic anemia (AA), allogeneic stem cell transplantation (ASCT) is the treatment of choice for younger patients with HLA-matched siblings. In patients older than 40 years, transplant-related mortality approaches 50% and survival does not differ between patients who receive ASCT and those who receive immunosuppressive therapy , In this age group, immunosuppressive therapy has been advocated as upfront therapy, with ASCT offered only for failed immunosuppressive therapy or relapse .